709 related articles for article (PubMed ID: 16946209)
21. Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis.
Escobar PF; Starks DC; Fader AN; Barber M; Rojas-Espalliat L
Gynecol Oncol; 2010 Oct; 119(1):43-7. PubMed ID: 20579712
[TBL] [Abstract][Full Text] [Related]
22. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
[TBL] [Abstract][Full Text] [Related]
23. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
Callahan MJ; Crum CP; Medeiros F; Kindelberger DW; Elvin JA; Garber JE; Feltmate CM; Berkowitz RS; Muto MG
J Clin Oncol; 2007 Sep; 25(25):3985-90. PubMed ID: 17761984
[TBL] [Abstract][Full Text] [Related]
24. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.
Carcangiu ML; Radice P; Manoukian S; Spatti G; Gobbo M; Pensotti V; Crucianelli R; Pasini B
Int J Gynecol Pathol; 2004 Jan; 23(1):35-40. PubMed ID: 14668548
[TBL] [Abstract][Full Text] [Related]
25. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?
Olivier RI; Lubsen-Brandsma LA; van Boven H; van Beurden M
Gynecol Oncol; 2005 Feb; 96(2):439-43. PubMed ID: 15661233
[TBL] [Abstract][Full Text] [Related]
26. A genetic epidemiological study of carcinoma of the fallopian tube.
Aziz S; Kuperstein G; Rosen B; Cole D; Nedelcu R; McLaughlin J; Narod SA
Gynecol Oncol; 2001 Mar; 80(3):341-5. PubMed ID: 11263928
[TBL] [Abstract][Full Text] [Related]
27. Timing of prophylactic hysterectomy-oophorectomy, mastectomy, and microsurgical breast reconstruction in BRCA1 and BRCA2 carriers.
Khansa I; Wang D; Coriddi M; Tiwari P
Microsurgery; 2014 May; 34(4):271-6. PubMed ID: 24123194
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
29. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
[TBL] [Abstract][Full Text] [Related]
30. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
[TBL] [Abstract][Full Text] [Related]
31. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation.
Finch A; Metcalfe KA; Chiang J; Elit L; McLaughlin J; Springate C; Esplen MJ; Demsky R; Murphy J; Rosen B; Narod SA
Psychooncology; 2013 Jan; 22(1):212-9. PubMed ID: 21913283
[TBL] [Abstract][Full Text] [Related]
32. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
Cass I; Holschneider C; Datta N; Barbuto D; Walts AE; Karlan BY
Obstet Gynecol; 2005 Dec; 106(6):1327-34. PubMed ID: 16319259
[TBL] [Abstract][Full Text] [Related]
33. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
[TBL] [Abstract][Full Text] [Related]
34. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
[TBL] [Abstract][Full Text] [Related]
35. Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy.
McEwen AR; McConnell DT; Kenwright DN; Gaskell DJ; Cherry A; Kidd AM
Gynecol Oncol; 2004 Mar; 92(3):992-4. PubMed ID: 14984974
[TBL] [Abstract][Full Text] [Related]
36. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
Armstrong K; Schwartz JS; Randall T; Rubin SC; Weber B
J Clin Oncol; 2004 Mar; 22(6):1045-54. PubMed ID: 14981106
[TBL] [Abstract][Full Text] [Related]
37. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
[TBL] [Abstract][Full Text] [Related]
38. BRCA2 germline mutations in primary cancer of the fallopian tube.
Casarsa S; Puglisi F; Baudi F; De Paola L; Venuta S; Piga A; Di Loreto C; Marchesoni D; D'Elia AV; Damante G
Oncol Rep; 2004 Aug; 12(2):313-6. PubMed ID: 15254695
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
Vicus D; Finch A; Cass I; Rosen B; Murphy J; Fan I; Royer R; McLaughlin J; Karlan B; Narod SA
Gynecol Oncol; 2010 Sep; 118(3):299-302. PubMed ID: 20570322
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT
Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
